{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-23-000004","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2023-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.075498+00:00","generated_at":"2026-06-20T06:01:43.490206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Pfizer FY2022 revenue record $100.3B, adj. EPS $6.58; FY2023 guidance $67-71B rev, adj. EPS $3.25-3.45","bullets":["Full-year 2022 revenues $100.3B (record), up 23% YoY; reported EPS $5.47, adjusted EPS $6.58.","Q4 revenues $24.3B, reported EPS $0.87, adjusted EPS $1.14.","FY2023 revenue guidance $67-71B (down ~31%), adjusted EPS $3.25-3.45 (down ~49% operational).","Excluding COVID products, Pfizer expects 7-9% operational revenue growth in 2023.","Completed ~$26B in acquisitions in 2022 (Biohaven, Arena, GBT); $9B dividends, $2B share repurchases."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-23-000004","json":"https://secwatch.observer/filing/0000078003-23-000004.json","markdown":"https://secwatch.observer/filing/0000078003-23-000004.md","text":"https://secwatch.observer/filing/0000078003-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000004/0000078003-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000004/pfe-20230131.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T06:01:43.490206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72134611a287fd5a98204f68451762076bb15034","claim":"PFIZER INC reported Full-Year 2022 results: revenue $100.3 Billion, EPS $5.47.","evidence_excerpt":"Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth – Excluding Contributions from Paxlovid and Comirnaty (1) , Revenues Grew 2% Operationally ▪ Strong Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth – Excluding Contributions from Paxlovid and Comirnaty (1) , Revenues Grew 5% Operationally ▪ Full-Year 2022 Reported Diluted EPS (2) of $5.47, Up 42% Year-Over-Year, and Adjusted Diluted EPS (3) of $6.58, Up 62% Year-Over-Year, Both of Which Represent All-Time Highs for Pfizer","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000004/0000078003-23-000004-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full-Year 2022"},{"label":"Revenue","value":"$100.3 Billion"},{"label":"EPS","value":"$5.47"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b78e5200bd1261ef11fc681d186fcd8749ade09c","claim":"PFIZER INC reported Full-Year 2023 results: revenue $67.0 to $71.0 Billion, EPS $3.25 to $3.45. Guidance initiated.","evidence_excerpt":"▪ Provides Full-Year 2023 Revenue Guidance (4) of $67.0 to $71.0 Billion and Adjusted Diluted EPS (3) Guidance of $3.25 to $3.45","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000004/0000078003-23-000004-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full-Year 2023"},{"label":"Revenue","value":"$67.0 to $71.0 Billion"},{"label":"EPS","value":"$3.25 to $3.45"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"ba2158485c9042f6a36820f5d07497d8ea10b5b6","claim":"PFIZER INC reported Fourth-Quarter 2022 results: revenue $24.3 Billion, EPS $0.87.","evidence_excerpt":"Strong Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth – Excluding Contributions from Paxlovid and Comirnaty (1) , Revenues Grew 5% Operationally ▪ Full-Year 2022 Reported Diluted EPS (2) of $5.47, Up 42% Year-Over-Year, and Adjusted Diluted EPS (3) of $6.58, Up 62% Year-Over-Year, Both of Which Represent All-Time Highs for Pfizer ▪ Fourth-Quarter 2022 Reported Diluted EPS (2) of $0.87, Up 48% Year-Over-Year, and Adjusted Diluted EPS (3) of $1.14, Up 45% Year-Over-Year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000004/0000078003-23-000004-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth-Quarter 2022"},{"label":"Revenue","value":"$24.3 Billion"},{"label":"EPS","value":"$0.87"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}